Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 262

1.

Impact of region of diagnosis, ethnicity, age, and gender on survival in acute myeloid leukemia (AML).

Acharya UH, Halpern AB, Wu QV, Voutsinas JM, Walter RB, Yun S, Kanaan M, Estey EH.

J Drug Assess. 2018 Jul 10;7(1):51-53. doi: 10.1080/21556660.2018.1492925. eCollection 2018.

2.

New drugs in AML: uses and abuses.

Estey EH, Gale RP, Sekeres MA.

Leukemia. 2018 Jun 6. doi: 10.1038/s41375-018-0168-z. [Epub ahead of print] No abstract available.

PMID:
29875431
3.

Incorporating Physical Function and Cognition Into Mortality Risk Assessment for Acute Myeloid Leukemia-Reply.

Sorror ML, Storer BE, Estey EH.

JAMA Oncol. 2018 Jul 1;4(7):1014-1015. doi: 10.1001/jamaoncol.2018.0677. No abstract available.

PMID:
29799988
4.

Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms.

Halpern AB, Othus M, Huebner EM, Scott BL, Becker PS, Percival MM, Hendrie PC, Gardner KM, Chen TL, Buckley SA, Orlowski KF, Anwar A, Appelbaum FR, Erba HP, Estey EH, Walter RB.

Leukemia. 2018 Apr 17. doi: 10.1038/s41375-018-0135-8. [Epub ahead of print]

PMID:
29720734
5.

Deep NPM1 Sequencing Following Allogeneic Hematopoietic Cell Transplantation Improves Risk Assessment in Adults with NPM1-Mutated AML.

Zhou Y, Othus M, Walter RB, Estey EH, Wu D, Wood BL.

Biol Blood Marrow Transplant. 2018 Apr 21. pii: S1083-8791(18)30198-8. doi: 10.1016/j.bbmt.2018.04.017. [Epub ahead of print]

PMID:
29684564
6.

A machine learning approach to integrate big data for precision medicine in acute myeloid leukemia.

Lee SI, Celik S, Logsdon BA, Lundberg SM, Martins TJ, Oehler VG, Estey EH, Miller CP, Chien S, Dai J, Saxena A, Blau CA, Becker PS.

Nat Commun. 2018 Jan 3;9(1):42. doi: 10.1038/s41467-017-02465-5.

7.

Unsatisfactory efficacy in randomized study of reduced-dose CPX-351 for medically less fit adults with newly diagnosed acute myeloid leukemia or other high-grade myeloid neoplasm.

Walter RB, Othus M, Orlowski KF, McDaniel EN, Scott BL, Becker PS, Percival MM, Hendrie PC, Medeiros BC, Chiarella MT, Louie AC, Estey EH.

Haematologica. 2018 Mar;103(3):e106-e109. doi: 10.3324/haematol.2017.182642. Epub 2017 Dec 14. No abstract available.

8.

Development and Validation of a Novel Acute Myeloid Leukemia-Composite Model to Estimate Risks of Mortality.

Sorror ML, Storer BE, Fathi AT, Gerds AT, Medeiros BC, Shami P, Brunner AM, Sekeres MA, Mukherjee S, Peña E, Elsawy M, Wardyn S, Whitten J, Moore R, Becker PS, McCune JS, Appelbaum FR, Estey EH.

JAMA Oncol. 2017 Dec 1;3(12):1675-1682. doi: 10.1001/jamaoncol.2017.2714.

PMID:
28880971
9.

Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 study.

Halpern AB, Othus M, Huebner EM, Buckley SA, Pogosova-Agadjanyan EL, Orlowski KF, Scott BL, Becker PS, Hendrie PC, Chen TL, Percival MM, Estey EH, Stirewalt DL, Walter RB.

Leukemia. 2017 Dec;31(12):2560-2567. doi: 10.1038/leu.2017.165. Epub 2017 May 30.

10.

Flow cytometric demonstration of decrease in bone marrow leukemic blasts after 'Day 14' without further therapy in acute myeloid leukemia.

Chen X, Othus M, Wood BL, Walter RB, Percival MM, Becker PS, Hendrie PC, Appelbaum FR, Estey EH.

Leuk Lymphoma. 2017 Nov;58(11):2717-2719. doi: 10.1080/10428194.2017.1307359. Epub 2017 Mar 28. No abstract available.

PMID:
28351184
11.

Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide.

Kayser S, Krzykalla J, Elliott MA, Norsworthy K, Gonzales P, Hills RK, Baer MR, Ráčil Z, Mayer J, Novak J, Žák P, Szotkowski T, Grimwade D, Russell NH, Walter RB, Estey EH, Westermann J, Görner M, Benner A, Krämer A, Smith BD, Burnett AK, Thiede C, Röllig C, Ho AD, Ehninger G, Schlenk RF, Tallman MS, Levis MJ, Platzbecker U.

Leukemia. 2017 Nov;31(11):2347-2354. doi: 10.1038/leu.2017.92. Epub 2017 Mar 21.

12.

Prognostic methylation markers for overall survival in cytogenetically normal patients with acute myeloid leukemia treated on SWOG trials.

Qu X, Othus M, Davison J, Wu Y, Yan L, Meshinchi S, Ostronoff F, Estey EH, Radich JP, Erba HP, Appelbaum FR, Fang M.

Cancer. 2017 Jul 1;123(13):2472-2481. doi: 10.1002/cncr.30626. Epub 2017 Feb 21.

13.

PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies.

Qazilbash MH, Wieder E, Thall PF, Wang X, Rios R, Lu S, Kanodia S, Ruisaard KE, Giralt SA, Estey EH, Cortes J, Komanduri KV, Clise-Dwyer K, Alatrash G, Ma Q, Champlin RE, Molldrem JJ.

Leukemia. 2017 Mar;31(3):697-704. doi: 10.1038/leu.2016.254. Epub 2016 Sep 22.

14.

Infusion of a non-HLA-matched ex-vivo expanded cord blood progenitor cell product after intensive acute myeloid leukaemia chemotherapy: a phase 1 trial.

Delaney C, Milano F, Cicconi L, Othus M, Becker PS, Sandhu V, Nicoud I, Dahlberg A, Bernstein ID, Appelbaum FR, Estey EH.

Lancet Haematol. 2016 Jul;3(7):e330-9. doi: 10.1016/S2352-3026(16)30023-0. Epub 2016 Jun 7.

PMID:
27374466
15.

Effect of measurable ('minimal') residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemia.

Othus M, Wood BL, Stirewalt DL, Estey EH, Petersdorf SH, Appelbaum FR, Erba HP, Walter RB.

Leukemia. 2016 Oct;30(10):2080-2083. doi: 10.1038/leu.2016.120. Epub 2016 May 2. No abstract available.

16.

Pre- and post-transplant quantification of measurable ('minimal') residual disease via multiparameter flow cytometry in adult acute myeloid leukemia.

Zhou Y, Othus M, Araki D, Wood BL, Radich JP, Halpern AB, Mielcarek M, Estey EH, Appelbaum FR, Walter RB.

Leukemia. 2016 Jul;30(7):1456-64. doi: 10.1038/leu.2016.46. Epub 2016 Feb 29.

17.

Prediction of early death in adults with relapsed or refractory acute myeloid leukemia.

Godwin CD, Othus M, Powell MA, Buckley SA, Estey EH, Walter RB.

Leuk Lymphoma. 2016 Oct;57(10):2421-4. doi: 10.3109/10428194.2015.1135436. Epub 2016 Jan 11. No abstract available.

18.

Does outcome of second salvage therapy in relapsed or refractory acute myeloid leukemia depend on intensity of either first or second salvage therapy?

Araki D, Othus M, Walter RB, Becker PS, Sandhu V, Estey EH.

Leuk Lymphoma. 2016 May;57(5):1205-7. doi: 10.3109/10428194.2015.1079316. Epub 2015 Dec 23. No abstract available.

PMID:
26694896
19.

Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?

Araki D, Wood BL, Othus M, Radich JP, Halpern AB, Zhou Y, Mielcarek M, Estey EH, Appelbaum FR, Walter RB.

J Clin Oncol. 2016 Feb 1;34(4):329-36. doi: 10.1200/JCO.2015.63.3826. Epub 2015 Dec 14.

20.

Resource Utilization and Safety of Outpatient Management Following Intensive Induction or Salvage Chemotherapy for Acute Myeloid Leukemia or Myelodysplastic Syndrome: A Nonrandomized Clinical Comparative Analysis.

Vaughn JE, Othus M, Powell MA, Gardner KM, Rizzuto DL, Hendrie PC, Becker PS, Pottinger PS, Estey EH, Walter RB.

JAMA Oncol. 2015 Nov;1(8):1120-7. doi: 10.1001/jamaoncol.2015.2969.

21.

Reply to D. Przepiorka et al.

Chen X, Xie H, Estey EH.

J Clin Oncol. 2015 Nov 1;33(31):3676-7. doi: 10.1200/JCO.2015.63.0749. Epub 2015 Aug 17. No abstract available.

PMID:
26282652
22.

Empiric definition of eligibility criteria for clinical trials in relapsed/refractory acute myeloid leukemia: analysis of 1,892 patients from HOVON/SAKK and SWOG.

Walter RB, Othus M, Löwenberg B, Ossenkoppele GJ, Petersdorf SH, Pabst T, Vekemans MC, Appelbaum FR, Erba HP, Estey EH.

Haematologica. 2015 Oct;100(10):e409-11. doi: 10.3324/haematol.2015.130013. Epub 2015 Jul 9. No abstract available.

23.

Prognostic significance of acquired copy-neutral loss of heterozygosity in acute myeloid leukemia.

Gronseth CM, McElhone SE, Storer BE, Kroeger KA, Sandhu V, Fero ML, Appelbaum FR, Estey EH, Fang M.

Cancer. 2015 Sep 1;121(17):2900-8. doi: 10.1002/cncr.29475. Epub 2015 May 29.

24.

Comparative analysis of flow cytometry and morphology for the detection of acute myeloid leukaemia cells in cerebrospinal fluid.

Loeb KR, Cherian S, Becker PS, Walter RB, Pagel JM, Abkowitz JL, Appelbaum FR, Wood BL, Estey EH.

Br J Haematol. 2016 Jan;172(1):134-6. doi: 10.1111/bjh.13465. Epub 2015 May 26. No abstract available.

PMID:
26010105
25.

A phase I/II study of oral clofarabine plus low-dose cytarabine in previously treated acute myeloid leukaemia and high-risk myelodysplastic syndrome patients at least 60 years of age.

Buckley SA, Mawad R, Gooley TA, Becker PS, Sandhu V, Hendrie P, Scott BL, Wood BL, Walter RB, Smith K, Dean C, Estey EH, Pagel JM.

Br J Haematol. 2015 Aug;170(3):349-55. doi: 10.1111/bjh.13437. Epub 2015 Apr 8.

PMID:
25854284
26.

Effect of allogeneic hematopoietic cell transplantation in first complete remission on post-relapse complete remission rate and survival in acute myeloid leukemia.

Araki D, Othus M, Walter RB, Sandhu V, Sandmaier BM, Becker PS, Appelbaum FR, Estey EH.

Haematologica. 2015 Jul;100(7):e254-6. doi: 10.3324/haematol.2014.118570. Epub 2015 Mar 20. No abstract available.

27.

Effect of genetic profiling on prediction of therapeutic resistance and survival in adult acute myeloid leukemia.

Walter RB, Othus M, Paietta EM, Racevskis J, Fernandez HF, Lee JW, Sun Z, Tallman MS, Patel J, Gönen M, Abdel-Wahab O, Levine RL, Estey EH.

Leukemia. 2015 Oct;29(10):2104-7. doi: 10.1038/leu.2015.76. Epub 2015 Mar 16. No abstract available.

28.

Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia.

Chen X, Xie H, Wood BL, Walter RB, Pagel JM, Becker PS, Sandhu VK, Abkowitz JL, Appelbaum FR, Estey EH.

J Clin Oncol. 2015 Apr 10;33(11):1258-64. doi: 10.1200/JCO.2014.58.3518. Epub 2015 Mar 2.

PMID:
25732155
29.

Idarubicin, cytarabine, and pravastatin as induction therapy for untreated acute myeloid leukemia and high-risk myelodysplastic syndrome.

Shadman M, Mawad R, Dean C, Chen TL, Shannon-Dorcy K, Sandhu V, Hendrie PC, Scott BL, Walter RB, Becker PS, Pagel JM, Estey EH.

Am J Hematol. 2015 Jun;90(6):483-6. doi: 10.1002/ajh.23981. Epub 2015 Feb 27.

30.

Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia.

Konopleva M, Thall PF, Yi CA, Borthakur G, Coveler A, Bueso-Ramos C, Benito J, Konoplev S, Gu Y, Ravandi F, Jabbour E, Faderl S, Thomas D, Cortes J, Kadia T, Kornblau S, Daver N, Pemmaraju N, Nguyen HQ, Feliu J, Lu H, Wei C, Wilson WR, Melink TJ, Gutheil JC, Andreeff M, Estey EH, Kantarjian H.

Haematologica. 2015 Jul;100(7):927-34. doi: 10.3324/haematol.2014.118455. Epub 2015 Feb 14.

31.

Low platelet count reduces subsequent complete remission rate despite marrow with <5% blasts after AML induction therapy.

Chen X, Newell LF, Xie H, Walter RB, Pagel JM, Sandhu VK, Becker PS, Hendrie PC, Abkowitz JL, Appelbaum FR, Estey EH.

Leukemia. 2015 Aug;29(8):1779-80. doi: 10.1038/leu.2015.23. Epub 2015 Feb 4. No abstract available.

PMID:
25650090
32.

The treatment-related mortality score is associated with non-fatal adverse events following intensive AML induction chemotherapy.

Buckley SA, Othus M, Estey EH, Walter RB.

Blood Cancer J. 2015 Jan 30;5:e276. doi: 10.1038/bcj.2014.97. No abstract available.

33.

Central nervous system involvement in acute myeloid leukemia patients undergoing hematopoietic cell transplantation.

Bar M, Tong W, Othus M, Loeb KR, Estey EH.

Biol Blood Marrow Transplant. 2015 Mar;21(3):546-51. doi: 10.1016/j.bbmt.2014.11.683. Epub 2014 Dec 26.

34.

G-CSF priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm.

Becker PS, Medeiros BC, Stein AS, Othus M, Appelbaum FR, Forman SJ, Scott BL, Hendrie PC, Gardner KM, Pagel JM, Walter RB, Parks C, Wood BL, Abkowitz JL, Estey EH.

Am J Hematol. 2015 Apr;90(4):295-300. doi: 10.1002/ajh.23927. Epub 2015 Jan 30.

35.

Correlation between peripheral blood and bone marrow regarding FLT3-ITD and NPM1 mutational status in patients with acute myeloid leukemia.

Tong WG, Sandhu VK, Wood BL, Hendrie PC, Becker PS, Pagel JM, Walter RB, Estey EH.

Haematologica. 2015 Mar;100(3):e97-8. doi: 10.3324/haematol.2014.118422. Epub 2014 Dec 19. No abstract available.

36.

Primacy of resistance rather than toxicity in determining outcome of therapy for AML.

Estey EH.

Clin Lymphoma Myeloma Leuk. 2014 Sep;14 Suppl:S56-8. doi: 10.1016/j.clml.2014.04.016. Review.

PMID:
25486956
37.

Acute myeloid leukemia: 2014 update on risk-stratification and management.

Estey EH.

Am J Hematol. 2014 Nov;89(11):1063-81. doi: 10.1002/ajh.23834. Review.

38.

Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center.

Walter RB, Othus M, Burnett AK, Löwenberg B, Kantarjian HM, Ossenkoppele GJ, Hills RK, Ravandi F, Pabst T, Evans A, Pierce SR, Vekemans MC, Appelbaum FR, Estey EH.

Leukemia. 2015 Feb;29(2):312-20. doi: 10.1038/leu.2014.242. Epub 2014 Aug 12.

39.

Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials.

Hills RK, Castaigne S, Appelbaum FR, Delaunay J, Petersdorf S, Othus M, Estey EH, Dombret H, Chevret S, Ifrah N, Cahn JY, Récher C, Chilton L, Moorman AV, Burnett AK.

Lancet Oncol. 2014 Aug;15(9):986-96. doi: 10.1016/S1470-2045(14)70281-5. Epub 2014 Jul 6. Review.

40.

Management of older or unfit patients with acute myeloid leukemia.

Walter RB, Estey EH.

Leukemia. 2015 Apr;29(4):770-5. doi: 10.1038/leu.2014.216. Epub 2014 Jul 9. Review.

41.

Factors associated with early reinduction chemotherapy for adults with acute myeloid leukemia.

Ueda M, Xie H, Sandhu RK, Walter RB, Pagel JM, Estey EH.

Leuk Lymphoma. 2015 Mar;56(3):782-4. doi: 10.3109/10428194.2014.928931. Epub 2014 Jul 17. No abstract available.

PMID:
24882254
42.

The past and future of CD33 as therapeutic target in acute myeloid leukemia.

Laszlo GS, Estey EH, Walter RB.

Blood Rev. 2014 Jul;28(4):143-53. doi: 10.1016/j.blre.2014.04.001. Epub 2014 Apr 21. Review.

PMID:
24809231
43.

Outpatient bendamustine and idarubicin for upfront therapy of elderly acute myeloid leukaemia/myelodysplastic syndrome: a phase I/II study using an innovative statistical design.

Lionberger JM, Pagel JM, Sandhu VK, Xie H, Shadman M, Mawad R, Boehm A, Dean C, Shannon-Dorcy K, Scott BL, Deeg HJ, Becker PS, Hendrie PC, Walter RB, Ostronoff F, Appelbaum FR, Estey EH.

Br J Haematol. 2014 Aug;166(3):375-81. doi: 10.1111/bjh.12905. Epub 2014 Apr 18.

44.

Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia.

Konopleva MY, Walter RB, Faderl SH, Jabbour EJ, Zeng Z, Borthakur G, Huang X, Kadia TM, Ruvolo PP, Feliu JB, Lu H, Debose L, Burger JA, Andreeff M, Liu W, Baggerly KA, Kornblau SM, Doyle LA, Estey EH, Kantarjian HM.

Clin Cancer Res. 2014 Apr 15;20(8):2226-35. doi: 10.1158/1078-0432.CCR-13-1978. Epub 2014 Feb 28.

45.

Outpatient management following intensive induction or salvage chemotherapy for acute myeloid leukemia.

Walter RB, Taylor LR, Gardner KM, Dorcy KS, Vaughn JE, Estey EH.

Clin Adv Hematol Oncol. 2013;11(9):571-7. Review.

46.

Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia.

Gyurkocza B, Gutman J, Nemecek ER, Bar M, Milano F, Ramakrishnan A, Scott B, Fang M, Wood B, Pagel JM, Baumgart J, Delaney C, Maziarz RT, Sandmaier BM, Estey EH, Appelbaum FR, Storer BE, Deeg HJ.

Biol Blood Marrow Transplant. 2014 Apr;20(4):549-55. doi: 10.1016/j.bbmt.2014.01.009. Epub 2014 Jan 16.

47.

Unsuccessful diagnostic cytogenetic analysis is a poor prognostic feature in acute myeloid leukaemia.

Medeiros BC, Othus M, Estey EH, Fang M, Appelbaum FR.

Br J Haematol. 2014 Jan;164(2):245-50. doi: 10.1111/bjh.12625. Epub 2013 Oct 28.

48.

Prediction of adverse events during intensive induction chemotherapy for acute myeloid leukemia or high-grade myelodysplastic syndromes.

Buckley SA, Othus M, Vainstein V, Abkowitz JL, Estey EH, Walter RB.

Am J Hematol. 2014 Apr;89(4):423-8. doi: 10.1002/ajh.23661. Epub 2014 Feb 24.

49.

Rapid rate of peripheral blood blast clearance accurately predicts complete remission in acute myeloid leukemia.

Vainstein V, Buckley SA, Shukron O, Estey EH, Abkowitz JL, Wood BL, Walter RB.

Leukemia. 2014 Mar;28(3):713-6. doi: 10.1038/leu.2013.341. Epub 2013 Nov 18. No abstract available.

PMID:
24240201
50.

Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase I/II study.

Walter RB, Medeiros BC, Gardner KM, Orlowski KF, Gallegos L, Scott BL, Hendrie PC, Estey EH.

Haematologica. 2014 Jan;99(1):54-9. doi: 10.3324/haematol.2013.096545. Epub 2013 Oct 18.

Supplemental Content

Loading ...
Support Center